CHRONIC HEPATITIS C DISEASE: WHO HAS COMPENSATED LIVER DISEASE AND HAS NOT BEEN PREVIOUSLY TREATED WITH INTERFERON ALPHA, WITH COMPENSATED LIVER DISEASE AND HISTOLOGICAL EVIDENCE OF CIRRHOSIS (CHILD-PUGH CLASS A) AND PATIENTS WITH HIV DISEASE THAT IS CLINICALLY STABLE
DOSE OF PEGASYS MONOTHERAPY FOR CHRONIC HEPATITIS C IS 180 ?G (1.0 ML VIAL OR 0.5 ML PREFILLED SYRINGE) ONCE WEEKLY FOR 48 WEEKS BY SUBCUTANEOUS ADMINISTRATION IN THE ABDOMEN OR THIGH.
PEGASYS AND COPEGUS COMBINATION THERAPY:--
THE RECOMMENDED DOSE OF PEGASYS WHEN USED IN COMBINATION WITH RIBAVIRIN FOR CHRONIC HEPATITIS C IS 180 ?G (1.0 ML VIAL OR 0.5 ML PREFILLED SYRINGE) ONCE WEEKLY. THE RECOMMENDED DOSE OF COPEGUS AND DURATION FOR PEGASYS/COPEGUS THERAPY IS BASED ON VIRAL GENOTYPE
THE DAILY DOSE OF COPEGUS IS 800 MG TO 1200 MG ADMINISTERED ORALLY IN TWO DIVIDED DOSES. THE DOSE SHOULD BE INDIVIDUALIZED TO THE PATIENT DEPENDING ON BASELINE DISEASE CHARACTERISTICS (E.G., GENOTYPE), RESPONSE TO THERAPY, AND TOLERABILITY OF THE REGIMEN.
CHRONIC HEPATITIS B DISEASE: ADULT PATIENTS WITH HBEAG POSITIVE AND HBEAG NEGATIVE WHO HAVE COMPENSATED LIVER DISEASE AND EVIDENCE OF VIRAL REPLICATION AND LIVER INFLAMMATION.